BILL BILLING Pharmaceutical Statistics
EDUCATION · MS-Meteorology/Applied Statistics; MA–Physiology; BS-Physics
EXPERIENCE · 2014-present, BioPharmaWorks · 2013-2014- Systamedic, Director Statistics and Clinical Science · 1991-2012- Pfizer,Senior Director and Statistics Head for Neuroscience Research Unit;1984-1991 USCG R&D Center, Research Statistician for Chemistry and Oceanography Branches · 1979-1984- Analysis & Technology, Statistical Analyst
EXPERTISE · Clinical and preclinical pharmaceutical statistics. Statistics support in all phases of drug development including regulatory filing/defense, clinical trial design/analysis, DSMB membership,due-diligence evaluation for investment and in-licensing decisions. Over 45 scientific publications and conference presentations
BIO
Bill is an applied statistician with over 38 years of experience in government and industry, the last 29 of which has been in the pharmaceutical industry. This included 21 years as a statistician at Pfizer Inc. and the last 8 years as a statistical consultant for several pharmaceutical and biotech companies. His interest in biomedicine began as an undergraduate at MIT, where he conducted research using Raman spectroscopy to study light triggered conformational changes in the rhodopsin protein. After receiving graduate degrees in physiology (Harvard) and applied statistics (MIT), Bill returned to Southeastern CT and began his career as an applied statistician. In 1991 Bill joined Pfizer Global Research and Development as a clinical statistician, where he was a member of development teams in the neuroscience and cardiovascular therapeutic areas. He provided statistical support to the successful Phase II/III program for dofetilide(Tikosyn™), for atrial fibrillation, and was the Global Lead Statistician for the varenicline (Chantix™/Champix™), aid to smoking cessation,phase III program and regulatory filing/defense. Subsequently, Bill led the statistical support to Pfizer’s development programs in neurodegeneration and psychiatric disorders.